Newfound Research LLC Raises Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Newfound Research LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 26.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,389 shares of the biopharmaceutical company’s stock after acquiring an additional 288 shares during the quarter. Newfound Research LLC’s holdings in Gilead Sciences were worth $86,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Aberdeen Wealth Management LLC lifted its position in shares of Gilead Sciences by 2.1% in the first quarter. Aberdeen Wealth Management LLC now owns 8,101 shares of the biopharmaceutical company’s stock valued at $482,000 after acquiring an additional 164 shares in the last quarter. Simmons Bank lifted its position in shares of Gilead Sciences by 0.4% in the first quarter. Simmons Bank now owns 41,962 shares of the biopharmaceutical company’s stock valued at $2,494,000 after acquiring an additional 166 shares in the last quarter. MFA Wealth Advisors LLC increased its stake in Gilead Sciences by 0.8% in the fourth quarter. MFA Wealth Advisors LLC now owns 20,095 shares of the biopharmaceutical company’s stock valued at $1,458,000 after purchasing an additional 167 shares during the last quarter. Rovin Capital UT ADV increased its stake in Gilead Sciences by 1.7% in the first quarter. Rovin Capital UT ADV now owns 10,188 shares of the biopharmaceutical company’s stock valued at $606,000 after purchasing an additional 172 shares during the last quarter. Finally, Adirondack Trust Co. increased its stake in Gilead Sciences by 6.9% in the first quarter. Adirondack Trust Co. now owns 2,710 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 175 shares during the last quarter. 78.58% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on GILD. Morgan Stanley upped their target price on Gilead Sciences from $63.00 to $65.00 and gave the company an “equal weight” rating in a research note on Friday, July 15th. Truist Financial upped their target price on Gilead Sciences from $71.00 to $76.00 and gave the company a “hold” rating in a research note on Thursday, September 15th. BMO Capital Markets assumed coverage on Gilead Sciences in a research note on Tuesday, June 7th. They issued a “hold” rating and a $63.00 target price for the company. Cantor Fitzgerald assumed coverage on Gilead Sciences in a research note on Tuesday, July 12th. They set a “neutral” rating and a $70.00 price target for the company. Finally, StockNews.com lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 17th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $73.53.

Gilead Sciences Stock Down 2.0 %

Shares of GILD stock traded down $1.25 during trading hours on Friday, reaching $62.52. The company had a trading volume of 402,144 shares, compared to its average volume of 7,683,103. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.27 and a current ratio of 1.43. Gilead Sciences, Inc. has a twelve month low of $57.17 and a twelve month high of $74.12. The company has a market capitalization of $78.36 billion, a P/E ratio of 19.13, a price-to-earnings-growth ratio of 0.61 and a beta of 0.31. The stock’s fifty day simple moving average is $63.22 and its 200 day simple moving average is $62.02.

Gilead Sciences (NASDAQ:GILDGet Rating) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.51 by $0.07. Gilead Sciences had a return on equity of 42.92% and a net margin of 15.03%. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $5.88 billion. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 6.63 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Thursday, September 15th will be issued a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a yield of 4.67%. The ex-dividend date is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is currently 89.02%.

About Gilead Sciences

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Articles

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.